Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
uniQure N.V. stock logo
QURE
uniQure
$19.35
-4.3%
$27.05
$8.73
▼
$51.72
$1.36B1.141.93 million shs2.10 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
uniQure N.V. stock logo
QURE
uniQure
0.00%-18.73%-16.27%-60.00%-30.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
uniQure N.V. stock logo
QURE
uniQure
$19.35
-4.3%
$27.05
$8.73
▼
$51.72
$1.36B1.141.93 million shs2.10 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
uniQure N.V. stock logo
QURE
uniQure
0.00%-18.73%-16.27%-60.00%-30.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
uniQure N.V. stock logo
QURE
uniQure
2.75
Moderate Buy$55.58187.25% Upside

Current Analyst Ratings Breakdown

Latest QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
uniQure N.V. stock logo
QURE
uniQure
Lower Price TargetBuy$80.00 ➝ $65.00
11/4/2026
uniQure N.V. stock logo
QURE
uniQure
Set Price Target$71.00
10/15/2026
uniQure N.V. stock logo
QURE
uniQure
Initiated CoverageBuy$27.00 ➝ $48.00
10/5/2026
uniQure N.V. stock logo
QURE
uniQure
DowngradeOverweight ➝ Equal Weight$60.00 ➝ $28.00
10/2/2026
uniQure N.V. stock logo
QURE
uniQure
Lower Price TargetOutperform$65.00 ➝ $48.00
9/30/2026
uniQure N.V. stock logo
QURE
uniQure
Lower Price TargetNeutral$46.00 ➝ $31.00
9/29/2026
uniQure N.V. stock logo
QURE
uniQure
Reiterated RatingOverweight$75.00
9/29/2026
uniQure N.V. stock logo
QURE
uniQure
Reiterated RatingBuy
9/23/2026
uniQure N.V. stock logo
QURE
uniQure
UpgradeStrong-Buy
9/21/2026
uniQure N.V. stock logo
QURE
uniQure
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 11/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
uniQure N.V. stock logo
QURE
uniQure
$16.10M84.30N/AN/A$4.20 per share4.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
uniQure N.V. stock logo
QURE
uniQure
-$198.97M-$3.51N/AN/AN/A-1,154.84%-96.34%-26.40%N/A

Latest QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.9154-$0.88+$0.0354-$0.88$6.18 million$5.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
uniQure N.V. stock logo
QURE
uniQure
0.17
11.52
11.52

Institutional Ownership

CompanyInstitutional Ownership
uniQure N.V. stock logo
QURE
uniQure
78.83%

Insider Ownership

CompanyInsider Ownership
uniQure N.V. stock logo
QURE
uniQure
4.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
uniQure N.V. stock logo
QURE
uniQure
22170.14 million66.88 millionOptionable

Recent News About These Companies

uniQure N.V. $QURE Stake Cut by Aberdeen Group plc
FY2026 Earnings Estimate for uniQure Issued By HC Wainwright
uniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $56.83
uniQure (NASDAQ:QURE) Stock Price Target Cut by HC Wainwright
uniQure stock: H.C. Wainwright cuts target to USD 65
Is uniQure (QURE) Priced Beyond Its Book Value Support?
uniQure (NASDAQ:QURE) Shares Up 5.6% - Here's Why
uniQure stock faces 2027 FDA decision after Q3 update
uniQure stock faces 2027 test after AMT-130 FDA review
uniQure (QURE) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

uniQure stock logo

uniQure NASDAQ:QURE

$19.35 -0.88 (-4.35%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$20.51 +1.16 (+6.00%)
As of 11/20/2026 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.